Neuronetics to Present at the Canaccord Genuity 44th Annual Growth Conference

Core Insights - Neuronetics, Inc. is a medical technology company focused on improving the quality of life for patients with neurohealth disorders through innovative treatments [4][5] - The company will present at the Canaccord Genuity 44th Annual Growth Conference on August 14, 2024, highlighting its commitment to investor engagement [4] Company Overview - Neuronetics is a global leader in neuroscience, emphasizing the importance of mental health alongside physical health [5] - The company's flagship product, NeuroStar Advanced Therapy, is a non-drug, noninvasive treatment designed for patients with major depressive disorder (MDD) and anxiety symptoms [5] - NeuroStar has delivered over 6.4 million treatments, establishing itself as the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults [5] Product Details - NeuroStar is indicated for treating depressive episodes and reducing anxiety symptoms in adults who have not responded satisfactorily to previous antidepressant medications [5] - The treatment is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescents aged 15-21 with MDD [5] - The company is dedicated to transforming lives through exceptional treatment outcomes [5]